



## Rallybio to Present at Upcoming Investor Conferences in November

November 8, 2023 at 8:00 AM EST

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov. 8, 2023-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

- **Stifel 2023 Healthcare Conference** in New York, NY on Wednesday, November 15, 2023. Steve Uden, M.D., Chief Executive Officer will present a corporate overview at 3:00 p.m. EST.
- **6th Annual Evercore ISI HealthCONx Conference** in Miami, FL on Tuesday, November 28, 2023. Steve Uden, M.D., Chief Executive Officer will participate in a fireside chat at 7:30 a.m. EST.

Live webcasts of both presentations will be accessible through the [Events and Presentations](#) section of Rallybio's website at [www.rallybio.com](http://www.rallybio.com). A replay of the webcasts will be available for 30 days following each presentation.

### About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.

Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit [www.rallybio.com](http://www.rallybio.com) and follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231028440323/en/): <https://www.businesswire.com/news/home/20231028440323/en/>

### Investor Contacts

Ami Bavishi  
Head of Investor Relations and Communications  
475-47-RALLY (Ext. 282)  
[abavishi@rallybio.com](mailto:abavishi@rallybio.com)

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

### Media Contact

Jorge Gaeta  
Mission North  
(516) 430-7659  
[Rallybio@missionnorth.com](mailto:Rallybio@missionnorth.com)

Source: Rallybio Corporation